Equasens

EQS

Equity

ISIN FR0012882389 / Valor 29127567

Euronext - Euronext Paris (2024-09-18)

EUR 46.50-0.75%

Equasens
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Equasens Group operates at the intersection of healthcare and technology, focusing on enhancing patient care through improved communication and data sharing among healthcare professionals and institutions. The company is structured into five divisions, each targeting a strategic area within the healthcare sector, including outpatient and hospital care services. As a leading provider of Healthcare IT solutions, Equasens develops software and innovative equipment designed to streamline the daily operations of healthcare providers. By facilitating the exchange of healthcare data between independent professionals and healthcare establishments, the company aims to improve the quality of patient care. This is achieved by fostering better coordination and integration across various segments of the healthcare system, thereby addressing the complexities of the City-Hospital-Medico-Social continuum.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Equasens reported a revenue increase of 2.6% for Q4 2023, reaching €219.7 million. This growth was driven by strengthened commercial forces and a notable performance in the "Observance" segment, which grew by 21.4% to €2.3 million.

Segment Performance

The "Observance" segment showed significant growth, increasing by 21.4% to €2.3 million in Q4 2023. This segment's performance was a key contributor to the overall revenue growth for Equasens during this period.

Medical Solutions Impact

Equasens's Medical Solutions segment experienced a decrease in activity by 12.4% to €8.9 million in Q4 2023. This decline was primarily due to an unfavorable base effect, with Ségur representing a smaller portion of the revenue compared to the previous year.

Outlook for 2024

Equasens's management is optimistic about 2024, projecting a growth in recurring revenues from maintenance and subscriptions by 9.2%, which would represent 35% of total revenue. The company also expects positive impacts from the full integration of recent acquisitions like Atoopharm, ADV, and Digipharmacie.

Dividend and Earnings Per Share

For Q4 2023, Equasens maintained a dividend yield of 2.3%. The earnings per share (EPS) for the year were adjusted to reflect a cautious outlook, with a projected EPS of €3.01 for 2023, a decrease of 6% from the previous year.

Summarized from source with an LLMView Source

Key figures

-38.0%1Y

-52.3%3Y

-17.6%5Y

Performance

41.2%1Y

33.5%3Y

33.4%5Y

Volatility